Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ankylosing spondylitis: an overview.

J Sieper1, J Braun, M Rudwaleit

  • 1Department of Gastroenterology and Rheumatology, UKBF, Free University, Hindenburgdamm 30, 12200 Berlin, Germany. hjsieper@zedat.fu-berlin.de

Annals of the Rheumatic Diseases
|October 17, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Epidemiologic and Immune Predictors of Atopic Dermatitis: Reduced Cord Blood Regulatory B10 Cells in the Munich Atopy Prediction Study (MAPS).

Allergy·2026
Same author

[Mummy research-Clinical consequences of Ötzi's arrow injury : German Congress for Orthopedics and Trauma Surgery (DKOU) science slam 2025].

Unfallchirurgie (Heidelberg, Germany)·2026
Same author

Effectiveness and cost-effectiveness of a multimodal, physiotherapist-led, vocational intervention for people with rheumatoid arthritis or axial spondyloarthritis and a reduced work ability: a randomized, controlled trial.

Rheumatology international·2025
Same author

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors.

Seminars in arthritis and rheumatism·2025
Same author

[Happiness-A concept for holistic person-centered healthcare in dermatology].

Dermatologie (Heidelberg, Germany)·2025
Same author

Performance of cut-offs of the ASAS Health Index to discriminate between treatment groups in patients with axial spondyloarthritis in the TICOSPA trial.

Seminars in arthritis and rheumatism·2024
Same journal

Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups.

Annals of the rheumatic diseases·2026
Same journal

A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus.

Annals of the rheumatic diseases·2026
Same journal

PD-1 signalling restrains pathogenic T peripheral helper and effector CD4⁺ T cell functions in rheumatoid arthritis.

Annals of the rheumatic diseases·2026
Same journal

Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma.

Annals of the rheumatic diseases·2026
Same journal

Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project.

Annals of the rheumatic diseases·2026
Same journal

Commentary on 'Assessing the performance of AI chatbots in answering patients common questions about low back pain'.

Annals of the rheumatic diseases·2026
See all related articles

Ankylosing spondylitis (AS) is a debilitating inflammatory disease impacting quality of life. While NSAIDs offer symptom relief, emerging biological therapies show promise in altering the disease course.

Area of Science:

  • Rheumatology and Immunology

Background:

  • Ankylosing spondylitis (AS) is a progressive, debilitating inflammatory disease with significant impact on patient productivity and quality of life.
  • The exact pathogenesis of AS remains unclear, but involves immune-mediated mechanisms, including human leucocyte antigen (HLA)-B27, cytokines, and genetic/environmental factors.

Purpose of the Study:

  • To review the current understanding of ankylosing spondylitis, including its diagnosis, pathogenesis, and treatment options.
  • To highlight the limitations of current treatments and the potential of emerging biological therapies.

Main Methods:

  • Diagnostic criteria for AS involve radiological sacroiliitis with clinical manifestations or inflammatory back pain with other spondyloarthropathy features.
  • Current first-line treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) for symptom relief.

Related Experiment Videos

Main Results:

  • NSAIDs provide symptomatic relief but do not alter the disease course.
  • Second-line treatments like corticosteroids and disease-modifying antirheumatic drugs offer limited benefit for refractory symptoms.

Conclusions:

  • Emerging biological therapies targeting inflammatory processes in AS offer potential to favorably alter the disease course beyond symptom relief.
  • Further research into AS pathogenesis is needed to develop more effective treatments.